Rantz: The AP’s BPC-157, RFK Jr. peptide story is advocacy, not journalism — and pharma profits might explain why
The AP's peptide story quoted zero supporters. Jason Rantz on what the FDA's BPC-157 review actually shows — and why pharma profits explain the coverage.
Lab vials represent the compounding pharmacy peptide compounds at the center of the FDA's BPC-157 debate ahead of the agency's July 23-24 advisory committee meeting. (Photo by George Frey/Getty Images)
(Photo by George Frey/Getty Images)
When the Associated Press published its latest warning about peptides this week, it pulled off something genuinely impressive. It wrote an entire piece about a health controversy without quoting a single physician, researcher, or patient who has had a positive experience with the compounds. Not one. In a field where thousands of doctors prescribe or recommend these substances and millions of patients report real results, the AP found zero supporters worth hearing from. If that sounds less like journalism and more like advocacy, that’s because it is.
The FDA announced it will hold a meeting in July to review whether certain peptides, including BPC-157, should be available for compounding pharmacies to produce again. This follows RFK Jr.’s push to end what he calls the FDA’s war on peptides, a crackdown that accelerated under Biden in 2023 when the agency quietly moved more than two dozen popular compounds onto a restricted list.
What the AP will not tell you is why the pharmaceutical industry has a very concrete interest in keeping the peptide crackdown permanent. For the larger picture on how federal health agencies have been weaponized against cheap alternatives to prescription drugs, this is a pattern worth watching.
Why Ozempic gets FDA praise while BPC-157 gets banned
Ozempic is a peptide. Semaglutide, its active ingredient, is a peptide-based compound that mimics the gut hormone GLP-1. It generated $26 billion in revenue for Novo Nordisk in 2024 alone. The FDA didn’t just approve it, it championed it. Nobody in the AP’s Rolodex called that a disaster in the works or warned about a Wild West situation.
But BPC-157, a compound that physicians and patients use for injury recovery and inflammation, with no serious adverse event pattern in that real-world use? That one requires wall-to-wall alarm coverage. The split has nothing to do with safety profiles. A pharmaceutical company owns Ozempic and charges accordingly.
Compounding pharmacies cut Big Pharma out — and that’s the real problem
A compounding pharmacy can produce a peptide for a fraction of the price, cutting Big Pharma out of the transaction entirely. The AP story, stripped of its scientific veneer, is a defense of that pricing model.
The pharmaceutical industry’s business model requires chronic treatment. A drug you take indefinitely generates far more revenue than one that actually fixes the underlying problem. Some physicians believe certain peptides can accelerate genuine healing rather than simply manage symptoms long term. The industry has every financial reason to see those compounds dismissed as unproven and kept off the market. Getting a science reporter to do that dismissing for you is even better than lobbying, because it comes with a press badge.
What RFK Jr. actually argued on the Joe Rogan podcast
RFK Jr. raised a genuine regulatory problem in his interview with Joe Rogan that the AP had no appetite for engaging with fairly.
“With the gray market you have no idea if you’re getting a good product,” Kennedy said. His argument is straightforward. When the FDA restricts a compound that patients want and doctors believe in, those patients don’t stop seeking it. They buy it from Chinese suppliers on TikTok for five dollars a vial with no quality control, no safety standards, and no physician in the loop.
Restricting compounding didn’t stop demand — it sent patients to Chinese suppliers
Moving production back to licensed domestic compounding pharmacies with a valid prescription requirement puts a doctor between the patient and the compound. Kennedy also said the Biden FDA had “illegally moved” the drugs onto the restricted list, a claim that at minimum deserves honest scrutiny rather than the dismissal it received.
Science without skeptics isn’t science
A news organization doing real health journalism would have found the orthopedic surgeons who use peptides in post-surgical recovery protocols, the researchers studying BPC-157 for ulcerative colitis, and the functional medicine physicians whose patients report outcomes their previous care couldn’t deliver. Those people exist. They’re not hiding.
The AP didn’t look for them because finding them would have ruined the story. They like casting RFK Jr. as a nut job. When every expert in a piece points the same direction and no dissent is permitted inside the frame, you’re not reading science coverage. You’re reading a campaign with a news organization’s logo on it.
“No Phase III data” is not the same as “no data”
Many of the specific compounded versions of peptides lack the standardized Phase III trial data the FDA requires for approval. That’s different from pretending there’s “no data.” There’s preclinical data, animal studies, human case reports, and in some cases small clinical trials. The FDA’s own notice on the July meeting actually cited potential medical uses for BPC-157, including treating ulcerative colitis.
If you don’t want to take peptides, then don’t. Moving them towards regulation and more study, however, is a good thing. It’s odd that the pro-choice crowd takes issue with patients working with their doctors to see if peptide use is right for them.
Listen to The Jason Rantz Show on weekday afternoons from 3 p.m. – 7 p.m. on Seattle Red on 770 AM (HD Radio 97.3 FM HD-Channel 3). Subscribe to the podcast here. Follow Jason Rantz on X, Instagram, YouTube, and Facebook.






Comments
1 Comments
The AP found zero supporters for peptides. Why weren't you able to find any other than RFK Jr and Joe Rogan? This article seems hypocritical at best.